Is Canafenib/Encofenib available in the Chinese market? where to buy

Encorafenib As an importantBRAF inhibitor, it has been approved in many countries around the world in recent years for the treatment of malignant tumors such as melanoma and colorectal cancer with BRAF V600E gene mutations. The good news for the Chinese market is that canafenib has been officially approved for marketing in China on June 30, 2025, with the trade name of encofenib capsules. This marks an important step for Chinese patients to obtain advanced targeted therapy drugs, filling the gap in domestic high-end BRAF inhibitors. However, given its short time on the market, the official pricing of encofenib has not yet been made public, and whether it will be included in medical insurance and the details of the reimbursement policy are still to be determined, which brings certain uncertainty to patients' financial burden and convenience of medication.

Currently, if domestic patients urgently need Canafenib, they can not only wait for inclusion in official medical insurance, but also purchase it through overseas channels. The European version of Canafenib has been sold in many countries. Common specifications include 75mg 42 capsules and 75mg 168 capsules. Patients can obtain the original drug through legal overseas drug procurement platforms or with the assistance of formal medical institutions.

In addition, generic drugs of canafenib have been produced in some countries such as Laos. The common specifications are75mg*90 tablets. The price is more affordable than the original drug, and the ingredients are basically the same as the original drug. Canafenib generics produced by manufacturers such as Lucius Pharmaceuticals and Daxiong Pharmaceuticals in Laos have been accepted by some patients in Southeast Asia and surrounding areas, becoming an option for patients with heavy financial burdens.

In the long run, with the launch of encofenib in China, it is expected to gradually enter the medical insurance directory in the future, which will greatly improve patient accessibility and affordability. When prescribing, doctors will also reasonably recommend the use of Encofenib original drug or high-quality generic drugs based on the patient's specific condition, financial status and medication needs.

Reference materials:https://www.braftovi.com/